Accolade Inc (ACCD)
9.415
+0.07
(+0.75%)
USD |
NASDAQ |
Apr 24, 16:00
9.415
0.00 (0.00%)
After-Hours: 19:38
Accolade Research and Development Expense (Quarterly): 23.47M for Nov. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| November 30, 2023 | 23.47M |
| August 31, 2023 | 25.60M |
| May 31, 2023 | 25.90M |
| February 28, 2023 | 24.08M |
| November 30, 2022 | 24.25M |
| August 31, 2022 | 26.19M |
| May 31, 2022 | 26.82M |
| February 28, 2022 | 22.37M |
| November 30, 2021 | 22.85M |
| August 31, 2021 | 22.51M |
| Date | Value |
|---|---|
| May 31, 2021 | 15.94M |
| February 28, 2021 | 13.33M |
| November 30, 2020 | 13.02M |
| August 31, 2020 | 12.24M |
| May 31, 2020 | 11.37M |
| February 29, 2020 | 8.711M |
| November 30, 2019 | 11.05M |
| August 31, 2019 | 11.30M |
| May 31, 2019 | 11.25M |
| February 28, 2019 | 9.822M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.711M
Minimum
Feb 2020
26.82M
Maximum
May 2022
18.54M
Average
22.37M
Median
Feb 2022
Research and Development Expense (Quarterly) Benchmarks
| HealthStream Inc | 11.93M |
| HealthEquity Inc | 55.24M |
| Trxade Health Inc | 0.3665M |
| Simulations Plus Inc | 1.312M |
| Schrodinger Inc | 51.49M |